Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk-Reference-Cited by-同舟云学术

Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk

Published:2017-05-31 Issue:11 Volume:32 Page:1304-1313
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Raaz-Schrauder Dorette^ORCID,Schrauder Michael G.,Stumpf Christian,Lewczuk Piotr,Kilian Tobias,Dietel Barbara,Garlichs Christoph D.,Schlundt Christian,Achenbach Stephan,Klinghammer Lutz

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/article/10.1007/s00380-017-0998-z/fulltext.html

Reference52 articles.

1. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292(4):490–495

2. Walsh MC, Choi Y (2014) Biology of the RANKL–RANK–OPG system in immunity, bone, and beyond. Front Immunol 5:511

3. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95(7):3597–3602

4. Collin-Osdoby P (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95(11):1046–1057

5. Caidahl K, Ueland T, Aukrust P (2010) Osteoprotegerin: a biomarker with many faces. Arterioscler Thromb Vasc Biol 30(9):1684–1686

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum levels of soluble receptor activator for nuclear factor kB ligand play a crucial role in the association of osteoprotegerin with coronary artery disease;Experimental and Therapeutic Medicine;2024-06-19

2. Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial;Journal of the American Heart Association;2024-03-05

3. The Relationship between Serum and Gene Expression Levels of RANK, RANKL and Osteoprotegerin Inflammatory Pathway with Unstable Angina: A Case-control Study;Iranian Journal of Allergy, Asthma and Immunology;2021-08-11

4. Serum TRACP5b, a Marker of Bone Resorption, Is Associated With Adverse Cardiac Prognosis in Hospitalized Patients With Heart Failure;CJC Open;2021-04

5. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5;Scientific Reports;2021-01-28